Optimizing Cotreatment of HCV and HIV Infection

This comprehensive program on managing HCV/HIV coinfection features an Interactive Decision Support Tool to compare your treatment choices with guideline recommendations, a CME/CE-certified educational module with accompanying downloadable slideset for fast and efficient learning, and more.
Annie Luetkemeyer Headshot
Annie Luetkemeyer, MD
Susanna Naggie, MD, MHS
Mark S. Sulkowski, MD


All PLWH who are coinfected with HCV should be offered curative HCV treatment. Nonadherence to ART or a lack of HIV suppression should not affect candidacy for treatment of HCV.

Mark S. Sulkowski, MD Released: November 8, 2018

Managing people living with both HIV and HCV and polypharmacy can be difficult. How do you analyze which HCV regimen to use and identify relevant drug interactions?

Annie Luetkemeyer Headshot Annie Luetkemeyer, MD Released: December 12, 2018

Treatment of HCV/HIV coinfection requires continued awareness of and attention to the complex drug–drug interactions that can occur, especially when using pharmacologically boosted ARVs and nonnucleoside reverse transcriptase inhibitors. Here’s my take on how to approach drug–drug interactions using patient cases.

Susanna Naggie, MD, MHS Released: January 25, 2019

Downloadable Audio

Listen as expert faculty answer clinicians’ questions about specific challenges in managing HCV/HIV coinfection, including how to apply guideline-based strategies, avoid common DAA and ART interactions, incorporate recent therapy approvals, and more.

Susanna Naggie, MD, MHS Released: September 13, 2018

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to get guideline-based treatment recommendations from Susanna Naggie, MD, MHS, and Mark S. Sulkowski, MD, for your patients with HCV/HIV coinfection.

Susanna Naggie, MD, MHS Mark S. Sulkowski, MD Released: August 6, 2018


Learn expert insights on choosing DAAs and ART for patients with HCV/HIV coinfection in this succinct and focused module.

Mark S. Sulkowski, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: July 20, 2018 Expiration: July 19, 2019

Gain expert perspective on selecting optimal DAA and ARV combinations for patients with HCV/HIV coinfection in this downloadable slideset.

Mark S. Sulkowski, MD Released: July 20, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an independent educational grant from
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?